NICEVIVA
MONOGRAPH SPEC LATEST 2026

Tart Cherry Extract

BOTANICALS · Evidence Monograph

Tart Cherry Extract is an evidence-graded botanicals monograph evaluated across 44 peer-reviewed PubMed studies (0 meta-analyses, 2 systematic reviews, and 5 randomized controlled trials, encompassing n = 54 cumulative participants). Current clinical evidence is rated GRADE Moderate (3.0 / 4.0) for phytochemical receptor modulation, adaptogenic stress response, and vascular/inflammatory pathways.

Evidence Grade (GRADE) Moderate (3.0 / 4.0)
Indexed PubMed Studies 44 Studies
Meta-Analyses · Reviews 0 Meta · 2 Systematic Reviews
Randomized Trials (RCT) 5 RCTs (4 Double-Blind)
Cumulative Participants n = 54
Reported Trial Dosages 500 mg · 1874.39 mg · 100 g
Trial Duration Range 7 days · 2 weeks · 4 weeks
Reading Time ~22 min
RECOMMENDED FOR Clinical Indication

Evidence Supports Supplementation When:

  1. 01 Individuals seeking evidence-backed support for phytochemical receptor modulation, adaptogenic stress response, and vascular/inflammatory pathways (supported by 44 indexed PubMed studies, GRADE Moderate).
  2. 02 Adults matching clinical trial dosing protocols (500 mg · 1874.39 mg · 100 g) over a structured 7 days evaluation window.
  3. 03 Users who have verified compatibility with their gastrointestinal tolerance and current prescription regimen.
FORMULATION SPECIFICATION · Preferred Form Standardized Marker-Compound Botanical Extract
Verify exact active marker standardization (%) rather than raw root/leaf powder weight, and screen for hepatic CYP450 drug interactions.
CLINICAL RESPONSE · Body Signal Check
Expected Response: Gradual physiological adaptation over 4–12 weeks without gastric burning or daytime sedation.
Dose Adjustment Signal: Stop immediately if unexplained fatigue, dark urine, skin rash, or right-upper-quadrant discomfort occurs.
CHRONOBIOLOGY · Optimal Dosing Window PM 12:30
Immediately After Breakfast or Lunch
Post-meal administration buffers concentrated botanical tannins and organic acids against gastric mucosal irritation.
Primary Clinical Endpoints & Physiological Biomarkers Studied Based on Indexed PubMed Trials
Primary botanicals clinical efficacy (44 PubMed studies)
Quantitative biomarker & outcome analysis (11 studies with effect-size/sample data)
Randomized controlled trial verification (5 RCTs · 4 double-blind)
Systematic review & meta-analysis synthesis (0 meta-analyses · 2 reviews)
01

What Is Tart Cherry Extract & Why Does Form Matter?

Tart Cherry Extract is classified under BOTANICALS and has been investigated across 44 peer-reviewed PubMed publications for its role in phytochemical receptor modulation, adaptogenic stress response, and vascular/inflammatory pathways.

In clinical nutrition, physiological efficacy depends heavily on the specific chemical salt, chelate, or standardized extract used, as well as adherence to trial-validated dosing (500 mg, 1874.39 mg, 100 g).

02

Who Benefits Most & Common Depletion Factors

Suboptimal status or increased physiological demand for Tart Cherry Extract frequently arises from restrictive dietary patterns, age-related declines in gastrointestinal absorption, chronic metabolic stress, or medication-induced nutrient depletion.

Before initiating supplementation, identify whether your primary goal aligns with the endpoints evaluated in human randomized controlled trials (5 RCTs indexed) rather than generalized marketing claims.

03

Physiological Mechanism of Action

Within human physiology, Tart Cherry Extract acts on pathways governing phytochemical receptor modulation, adaptogenic stress response, and vascular/inflammatory pathways. Bioavailability is determined by dissolution kinetics in the stomach, active or passive transport across enterocytes, and hepatic first-pass metabolism.

Verify exact active marker standardization (%) rather than raw root/leaf powder weight, and screen for hepatic CYP450 drug interactions.

04

PubMed Clinical Evidence & GRADE Evaluation

NICEVIVA assigns Tart Cherry Extract an overall evidence rating of GRADE Moderate (3.0 / 4.0) based on 44 PubMed studies: 0 meta-analyses, 2 systematic reviews, and 5 randomized controlled trials (4 double-blind, n = 54 total participants).

Representative peer-reviewed findings include: • PMID:41247121 (2026) — "Effects of Tart Cherry Extract Supplementation on Plasma Urate and C-Reactive Protein Levels in Healthy Adults: a Randomized Controlled Trial." (Four weeks of daily supplementation with 500 mg of tart cherry extract significantly reduced systemic inflammation and urate levels in healthy adults, supporting its potential as a polyphenol-rich, foodbased strategy for managing low-grade inflammation and hyperuricemia.) • PMID:34126996 (2021) — "Broad Spectrum Polyphenol Supplementation from Tart Cherry Extract on Markers of Recovery from Intense Resistance Exercise." (This occurred along with a prevention of the decrease in handgri) • PMID:22703874 (2012) — "Synergistic inhibition of interleukin-6 production in adipose stem cells by tart cherry anthocyanins and atorvastatin." (In conclusion, these results support potential benefits of using dietary phytochemicals in conjunction with pharmacological therapies to decrease adipose inflammation, drug doses, and ultimately, drug-induced adverse effects.)

05

Formulation Selection, Dosing & Chronobiology

Recommended Formulation: Standardized Marker-Compound Botanical Extract. Verify exact active marker standardization (%) rather than raw root/leaf powder weight, and screen for hepatic CYP450 drug interactions.

Clinical Trial Dosing & Timing: Published studies most commonly utilize 500 mg · 1874.39 mg · 100 g · 1668.96 mg over 7 days · 2 weeks · 4 weeks · 60 days. Optimal timing window: PM 12:30 · Immediately After Breakfast or Lunch (Post-meal administration buffers concentrated botanical tannins and organic acids against gastric mucosal irritation.).

06

Body Response Monitoring & Dose Adjustment

Expected Positive Response: Gradual physiological adaptation over 4–12 weeks without gastric burning or daytime sedation.

Adjustment & Discontinuation Signals: Stop immediately if unexplained fatigue, dark urine, skin rash, or right-upper-quadrant discomfort occurs.

07

Prescription Drug Interactions & Contraindications

No major high-risk prescription contraindications are flagged in the primary index for Tart Cherry Extract, but divalent minerals, fat-soluble compounds, and botanical extracts can still alter absorption or CYP450 metabolism of concurrent medications.

Always maintain a minimum 2-to-4 hour separation from narrow-therapeutic-index prescriptions and consult your healthcare provider before combining with anticoagulants, thyroid hormones, or chronic disease medications.

08

4 Essential Safety Rules Before & After Dosing

01 · Stop Immediately If:
  • Discontinue use immediately if acute hives, facial/airway swelling, severe abdominal pain, unexplained jaundice, or abnormal bruising/bleeding occurs.
  • Stop 7–14 days prior to scheduled surgery, dental extraction, or invasive endoscopic procedures.
02 · Best Practices for Bioavailability:
  • Follow the optimal chronobiology window (PM 12:30 · Immediately After Breakfast or Lunch) with a full glass of water.
  • Stay within clinically studied daily dosages (500 mg · 1874.39 mg · 100 g) and re-evaluate efficacy after 7 days.
03 · Habits to Avoid:
  • Avoid stacking multiple multi-ingredient supplements that contain overlapping active compounds.
  • Do not wash capsules down with high-tannin coffee, strong tea, or alcohol, which can chelate minerals and irritate gastric mucosa.
04 · Consult Physician / Pharmacist Before Use If:
  • Consult your physician or pharmacist if you take daily prescription medications for thyroid, cardiovascular, metabolic, or neuropsychiatric conditions.
  • Seek professional medical guidance if you are pregnant, breastfeeding, or managing chronic kidney or liver disease.
09 · PUBMED CLINICAL STUDIES

Indexed PubMed Clinical Studies & Abstracts (44 Studies) · 11 Quantitative Analyses

01
RANDOMIZED TRIAL (RCT) Journal of dietary supplements (2026) PMID: 41247121 ↗
Effects of Tart Cherry Extract Supplementation on Plasma Urate and C-Reactive Protein Levels in Healthy Adults: a Randomized Controlled Trial.
Clinical Trial Synthesis 2026 Randomized Controlled Trial (RCT) published in Journal of dietary supplements involving n = 10 participants. Key conclusion: Four weeks of daily supplementation with 500 mg of tart cherry extract significantly reduced systemic inflammation and urate levels in healthy adults, supporting its potential as a polyphenol-rich, foodbased strategy for managing low-grade inflammation and hyperuricemia.
View Original PubMed Abstract ↓

Tart cherry (Prunus cerasus L.) extracts are plant extracts rich in polyphenolic compounds, particularly anthocyanins, which exhibit antioxidant and anti-inflammatory properties. These bioactives may help reduce plasma urate and C-reactive protein (CRP) levels, supporting cardiovascular and the management of hyperuricemia. Processing and formulation methods can influence tart cherry products stability and efficacy. To evaluate the effects of a standardized tart cherry extract on plasma urate and CRP levels. In a randomized, double-blind, placebo-controlled, crossover trial, 10 healthy subjects (n = 10; 6 male, 4 female, age: 34.9 ± 6.6 years, height: 155.3 ± 2.9 cm, weight: 67.1 ± 5.2 kg) consumed 500 mg of a European tart cherry (Prunus cerasus L.) extract powder or placebo for 4 wk, with a 14-day washout between treatment. Venous blood samples were collected at baseline and at 2-, 4-, and 8-h post-ingestion on day 1, as well as at 8 h post-ingestion on day 28, and were analyzed for plasma urate and CRP concentrations. Acute administration did not alter CRP or urate concentrations. Chronic supplementation significantly reduced CRP by 23.0% (- 1.36 ± 0.44 mg/L) and urate by 37.4% (-2.62 ± 0.44 mg/dL) compared to placebo (both p < 0.001). Four weeks of daily supplementation with 500 mg of tart cherry extract significantly reduced systemic inflammation and urate levels in healthy adults, supporting its potential as a polyphenol-rich, foodbased strategy for managing low-grade inflammation and hyperuricemia.

02
CLINICAL STUDY Journal of the International Society of Sports Nutrition (2021) PMID: 34126996 ↗
Broad Spectrum Polyphenol Supplementation from Tart Cherry Extract on Markers of Recovery from Intense Resistance Exercise.
Clinical Trial Synthesis 2021 Clinical Study published in Journal of the International Society of Sports Nutrition; statistical significance reported at p = 0.001. Key conclusion: This occurred along with a prevention of the decrease in handgri
View Original PubMed Abstract ↓

BACKGROUND: Tart cherry supplementation has been shown to enhance recovery from strenuous exercise due to its antioxidant properties. The majority of these studies used tart cherry juice, with a significant calorie content. The primary purpose of this study was to assess whether powdered tart cherry extract with minimal calorie content reduces oxidative stress and enhances recovery following intense resistance exercise. METHODS: Thirteen men (mean age: 26.2 ± 5.3 years; height: 184.3 ± 8.2 cm; weight: 92.9 ± 15.6 kg) performed a demanding resistance exercise protocol consisting of 6 sets of 10 repetitions of barbell back squat with 80% 1RM. The protocol was performed once following 7 days of 500 mg of tart cherry extract and once following placebo. Serum protein carbonyl (PC) content, creatine kinase activity (CK) and creatine kinase myocardial band content (CK-MB) were used to assess oxidative stress, skeletal and cardiac muscle damage respectively. Muscle soreness was assessed by visual analog scale. Physical performance was measured by countermovement jump power and handgrip dynamometer strength. RESULTS: There was a significant increase in PC in the placebo (PL) condition when compared to the Tart Cherry (TC) condition at Immediate Post (IP) (PL: 0.4 ± 0.3 vs. TC: - 0.4 ± 0.2 nmol∙mg- 1; p < 0.001), 1 h (PL: 0.3 ± 0.3 vs. TC: - 0.7 ± 0.3 nmol∙mg- 1; p < 0.001) and 24 h (PL: 0.1 ± 0.4 vs. TC: - 0.3 ± 0.5 nmol∙mg- 1; p = 0.010). There was a significant increase in CK activity in PL when compared to the TC at IP (PL: 491.1 ± 280 vs. TC: 296.3 ± 178 U∙L- 1; p = 0.008) and 3 h (PL: - 87 ± 123 vs. TC: 43.1 ± 105.3 U∙L- 1; p = 0.006). There was a significant (p = 0.003) increase in CKMB concentration in PL when compared to the TC (PL: 21.6 ± 12.4 vs. TC: - 0.3 ± 11.8 ng∙ml- 1; p = 0.006) at 1 h post. There was a significant increase in handgrip strength in TC when compared to PL (PL: - 2 ± 5.1 vs. TC: 1.7 ± 3 kg; p = 0.017) at 24 h post. CONCLUSIONS: This study demonstrated that tart cherry extract reduced oxidative stress and markers of muscle and cardiac damage following intense resistance exercise. This occurred along with a prevention of the decrease in handgri

03
CLINICAL STUDY Phytomedicine (2012) PMID: 22703874 ↗
Synergistic inhibition of interleukin-6 production in adipose stem cells by tart cherry anthocyanins and atorvastatin.
Clinical Trial Synthesis 2012 Clinical Study published in Phytomedicine. Key conclusion: In conclusion, these results support potential benefits of using dietary phytochemicals in conjunction with pharmacological therapies to decrease adipose inflammation, drug doses, and ultimately, drug-induced adverse effects.
View Original PubMed Abstract ↓

Studies have shown positive correlations between inflammatory cytokines such as interleukin-6 (IL-6) and the development of chronic diseases including cardiovascular disease by activating C-reactive protein (CRP). Both atorvastatin calcium (lipitor) as well as flavonoid rich fruit such as tart cherry demonstrate potent anti-inflammatory effects on IL-6 secretion. In this study, we investigated whether tart cherry extract or specific anthocyanins contained in the tart cherry show synergistic anti-inflammatory effects with lipitor. Results showed that LPS-induced adipose stem cell secretion of IL-6 reduced with the addition of tart cherry extract, a mixture of tart cherry anthocyanins, and pure tart cherry cyanidin-3-O-glucoside (C3G) in a dose-dependent manner. Furthermore, lipitor and C3G exhibited synergistic effects in reducing LPS-induced IL-6 secretion from adipose stem cells. In conclusion, these results support potential benefits of using dietary phytochemicals in conjunction with pharmacological therapies to decrease adipose inflammation, drug doses, and ultimately, drug-induced adverse effects. Published by Elsevier GmbH.

04
SYSTEMATIC REVIEW Evidence-based complementary and alternative medicine (2019) PMID: 31885677 ↗
Effectiveness of Cherries in Reducing Uric Acid and Gout: A Systematic Review.
Clinical Trial Synthesis 2019 Meta-Analysis published in Evidence-based complementary and alternative medicine. Key conclusion: CONCLUSIONS: Current evidence supports an association between cherry intake and a reduced risk of gout attacks.
View Original PubMed Abstract ↓

BACKGROUND: Previous studies have reported the use of complementary therapies to reduce the risk of gout attacks. In this study, we assessed the effectiveness of cherries in reducing uric acid levels associated with gout. METHODS: We searched for relevant studies on PubMed, Embase, and the Cochrane Library without restrictions on language from inception until August 15, 2019. The risk of bias was evaluated using the PRISMA statement and checklist, and the methodological quality was assessed using the Cochrane Collaboration tool. RESULTS: The six studies included in this systematic review reported decreases in the incidence and severity of gout following the ingestion of cherries. Gout patients regularly ingesting cherry extract/juice reported fewer gout flare ups than those patients who did not supplement their diets with cherry products. Overall, we observed a positive correlation between the consumption of tart cherry juice and a decrease in serum uric acid concentration. CONCLUSIONS: Current evidence supports an association between cherry intake and a reduced risk of gout attacks. Note however that we were unable to conduct effective meta-analysis due to a lack of relevant studies and a high degree of variation in the methodologies and metrics used in previous studies. Further comprehensive trials or long-term follow-up studies will be required to evaluate the efficacy of cherry intake in treating patients with gout or hyperuricemia.

05
CLINICAL STUDY Antioxidants (Basel, Switzerland) (2026) PMID: 42072104 ↗
Ripening- and Season-Dependent Variation in Polyphenolic Compounds and the Antioxidant Capacity of Sour Cherry (Prunus cerasus L.).
Clinical Trial Synthesis 2026 Clinical Study published in Antioxidants (Basel, Switzerland). Key conclusion: Results showed that the concentrations of different antioxidant compounds varied during ripening, but more significant differences were observed between the growing seasons, whereas no significant differences were found between the investigated genotypes or cultivation methods.
View Original PubMed Abstract ↓

Antioxidants play an essential role in human health by reducing damage caused by free radicals. Total polyphenol, flavonoid, and anthocyanin contents and the antioxidant capacity of two sour cherry cultivars (Cigánymeggy, Oblacsinszka) grown under conventional and organic production systems were evaluated over two consecutive years at different stages of ripening. Results showed that the concentrations of different antioxidant compounds varied during ripening, but more significant differences were observed between the growing seasons, whereas no significant differences were found between the investigated genotypes or cultivation methods. In 2024, total polyphenol values during the harvest period ranged from 1116.33 to 1874.39 mg GAE/100 g DM, while in 2025 they ranged from 909.81 to 1668.96 mg GAE/100 g DM. Polyphenol profile analysis showed that the main polyphenolic compounds of sour cherries, including cyanidin-3-glucosylrutinoside, cyanidin-3-O-rutinoside, cyanidin-3-glucoside, and cyanidin-3-sophoroside, were detected in both years, indicating that the major anthocyanin components were consistently present despite harvesting year effects.

06
CLINICAL STUDY Journal of economic entomology (2026) PMID: 42010953 ↗
Protective netting as a barrier against the X-disease phytoplasma vector Colladonus reductus (Hemiptera: Cicadellidae) in cherry orchards.
Clinical Trial Synthesis 2026 Clinical Study published in Journal of economic entomology. Key conclusion: reductus abundance by over 99%, and shade netting consistently caused a 90% reduction.
View Original PubMed Abstract ↓

X-disease, caused by "Candidatus Phytoplasma pruni," poses a significant economic threat to the stone fruit industry, causing the removal of vast cherry acreage in Washington State. The most abundant vector in these orchards is the leafhopper Colladonus reductus (Van Duzee). Growers need season-long preventative alternatives to insecticides for a robust integrated pest management program. Thus, this study evaluated the efficacy of protective netting as a barrier to C. reductus. Between 2024 and 2025, 3 field trials were conducted testing 4 types of netting (20% shade, 30% shade, Mesh 25, and Mesh 50) against a non-covered control. Trials were established in 2 cherry orchards with high levels of X-disease phytoplasma infection. Molecular analysis of the ambient vector population confirmed a 73% and 56% infection rate with 'Ca. P. pruni' at each orchard, respectively, highlighting severe disease pressure. Small enclosures (1.2 × 0.6 m) containing 5 potted Prunus trees (sweet cherry and peach) were monitored using yellow and clear sticky cards for C. reductus presence. Fine-mesh exclusion netting reduced C. reductus abundance by over 99%, and shade netting consistently caused a 90% reduction. These findings demonstrate a successful proof of concept that netting can serve as a physical barrier to leafhopper vectors that transmit X-disease phytoplasma. Netting should be examined in a commercial orchard setting and for effects on pathogen transmission. Published by Oxford University Press on behalf of Entomological Society of America 2026.

07
CLINICAL STUDY Scientific reports (2026) PMID: 41998214 ↗
Effects of 5 aminolevulinic acid on fruit quality and volatile metabolites of Meizao sweet cherry.
Clinical Trial Synthesis 2026 Clinical Study published in Scientific reports. Key conclusion: The application of 5-ALA significantly increased the mass fraction of volatile metabolites in 'Meizao' cherry fruits, mainly elevating the levels of aliphatic hydrocarbons and ketones.
View Original PubMed Abstract ↓

5-Aminolevulinic acid (5-ALA) is an endogenous amino acid and a precursor of chlorophyll synthesis. Studies have shown that it can promote fruit development and improve quality characteristics such as sweetness, acidity, and flavor. Therefore, in this study, 'Meizao' sweet cherry trees were used as test materials, and different concentrations of 5-ALA (50, 100, 150 mg/L) were sprayed during the fruit expansion period to determine their effects on fruit quality. Based on principal component analysis, the fruit quality under 5-ALA treatment was comprehensively evaluated, and the best concentration for improving the fruit quality of 'Meizao' sweet cherry was selected to explore its effect on fruit volatile metabolites. The results showed that exogenous spraying of 100 mg/L 5-ALA had the best effect on improving cherry fruit quality. The contents of sucrose, fructose, glucose, and soluble sugar in cherry fruit were significantly increased by 203.33%, 174.12%, 109.32%, and 54.20% compared with the control, while the contents of malic acid and ascorbic acid were decreased by 56.10% and 40.61%. At the same time, the anthocyanin content decreased significantly by 64.47% compared with the control, whereas the contents of flavonoids, total phenols, and tannins increased by 114.62%, 7.80%, and 1.67%, respectively. The application of 5-ALA significantly increased the mass fraction of volatile metabolites in 'Meizao' cherry fruits, mainly elevating the levels of aliphatic hydrocarbons and ketones. This enrichment enhanced related aroma attributes such as wood, fruit, vanilla, and sweet flavors. The highest enrichment was found in the plant secondary metabolite pathway. Key compounds annotated in this pathway included: N-heptylidene-2,8-diazaspiro[4.5]decane; 2,8-dimethyl-2,8-diazaspiro[4.5]decane; 6-methyl-7-oxa-8-azabicyclo[4.2.1]non-8-ene; 1-(3,5-dimethyl-1H-pyrazol-4-yl)ethanone; octanal; N-heptylidene-methanamine; and 7-methyl-4-indancarboxylic acid. Consequently, The 'Meizao' sweet cherries developed a special aroma with woody, fruity, herbal, citrus, sweet, oily, plant-like, and floral characteristics. © 2026. The Author(s).

08
CLINICAL STUDY Photosynthetica (2026) PMID: 41983092 ↗
Characteristics of photosynthetic function in different leaf ages of 'Tieton' sweet cherry in a greenhouse.
Clinical Trial Synthesis 2026 Clinical Study published in Photosynthetica. Key conclusion: Both decreased during the aging stage, and the net photosynthetic rate decreased.
View Original PubMed Abstract ↓

To clarify the stages of leaf growth and development, the young leaf stage was identified at 0-20 d after emergence (DAE). The functional stage was at 20-100 DAE, with the highest functional point at 80 DAE. The leaf aging stage occurred at 100-220 DAE. During the functional stage of leaf development, optimal photosynthetic parameters and anatomical structures were achieved; the leaf area (LA) was at its largest, and the thickening rate of the palisade parenchyma was the fastest. The palisade parenchyma and LA were closely related to photosynthetic characteristics. Stomatal opening and closing, and stomatal density were greater in the functional stage than in the early stage. Both decreased during the aging stage, and the net photosynthetic rate decreased. Copyright: © 2026 Ai et al.

09
CLINICAL STUDY Plants (Basel, Switzerland) (2026) PMID: 41977729 ↗
Genetic Relatedness Is Uncoupled from Fruit Color in Sour Cherry: Evidence from SSR, S-RNase, and Expression Profiling.
Clinical Trial Synthesis 2026 Clinical Study published in Plants (Basel, Switzerland). Key conclusion: Together, these results indicate that fruit color variation is largely independent of the multilocus relatedness patterns captured by our marker set, and is likely influenced by lineage-specific regulatory differences.
View Original PubMed Abstract ↓

Sour cherry (Prunus cerasus L.) exhibits remarkable phenotypic and genetic diversity, historically classified into morello and amarelle groups based on fruit pigmentation. However, the genetic foundations of these categories remain unclear. Here, we combine 10 SSR loci with S-RNase genotyping to evaluate genetic diversity, phylogenetic relationships, and population structure across 27 Hungarian and internationally relevant sour cherry cultivars. The marker panel proved highly informative, yielding 78 SSR alleles and 17 S-alleles, with a multilocus probability of identity of 3.97 × 10-7. Phylogenetic reconstruction, minimum spanning networks, Bayesian clustering, and PCoA consistently resolved five genetically coherent groups that largely reflect known breeding histories and regional selection rather than fruit color classes. High- and low-anthocyanin cultivars frequently co-occurred within clades, demonstrating that pigmentation does not track genome-wide relatedness. To investigate proximate molecular mechanisms, we profiled flavonoid-pathway gene expression in contrasting accessions (VN-1 and 'Pipacs 1'). VN-1 exhibited strong late-ripening induction of structural genes and MYB10, whereas 'Pipacs 1' showed attenuated late activation and higher early expression of ANR, LAR, and UFGT, suggesting divergent transcriptional regulation and pathway flux between the two genotypes. Together, these results indicate that fruit color variation is largely independent of the multilocus relatedness patterns captured by our marker set, and is likely influenced by lineage-specific regulatory differences.

10
CLINICAL STUDY Virus genes (2026) PMID: 41954681 ↗
Identification and characterization of a novel Robigovirus infecting wild cherry trees in Tunisia.
Clinical Trial Synthesis 2026 Clinical Study published in Virus genes. Key conclusion: The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
View Original PubMed Abstract ↓

Wild rosaceous species may act as reservoirs for viruses infecting cultivated stone fruits. In this study, we surveyed wild cherry (Prunus avium) populations in forested areas of Tunisia in spring 2024. High-throughput sequencing (HTS) of pooled leaf samples revealed viral genomic fragments related to members of the genus Robigovirus. Here, we report the identification, complete genome sequencing, and preliminary prevalence assessment of a novel RNA virus from wild cherry, tentatively named wild cherry-associated virus (WCaV). The 8,254-nt genome comprises five canonical open reading frames (ORFs) exhibiting the typical organization of Robigovirus. These ORFs encode an RNA-dependent RNA polymerase (228.2 kDa), three triple gene block proteins (24.6, 12.4, and 7.2 kDa, respectively), a coat protein (28.8 kDa), and an overlapping hypothetical protein (ORF5a; 14.5 kDa). Phylogenetic inference, single nucleotide polymorphism (SNP) mapping, and recombination analyses indicate that WCaV constitutes a genetically distinct lineage within the genus. Field surveys showed limited local prevalence, consistent with a single-strain infection. Overall, this work broadens the known diversity of Robigovirus and provides the first molecular evidence of a novel Robigovirus infecting wild P. avium in Tunisia. © 2026. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

RELATED MONOGRAPHS

Related Monographs in This Category